Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CLK1 | P49759 | 2/20 | 0.52 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.52 |
| ▸ | DYRK1B | Q9Y463 | 2/20 | 0.52 |
| ▸ | F9 | P00740 | 11/20 | 0.44 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.44 |
| ▸ | F10 | P00742 | 7/20 | 0.43 |
| ▸ | ACACB | O00763 | 1/20 | 0.42 |
| ▸ | ACACA | Q13085 | 1/20 | 0.42 |
| ▸ | RXRA | P19793 | 1/20 | 0.42 |
| ▸ | RXRB | P28702 | 1/20 | 0.42 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | PTGES | O14684 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3498352 | 0.89 | MCL1 (0.50) | CLK1DYRK1ADYRK1BF9MCL1 | |
| SCHEMBL3499504 | 0.84 | F9 (0.47) | F9MCL1F10NR1H4PTGES | |
| SCHEMBL121774 | 0.80 | F9 (0.63) | CLK1DYRK1ADYRK1BF9F10 | |
| SCHEMBL3496932 | 0.73 | CLK1 (0.55) | CLK1DYRK1ADYRK1BF9F10 | |
| SCHEMBL30837260 | 0.71 | KMT2A (0.63) | MCL1ACACBACACARXRARXRB | |
| SCHEMBL17858432 | 0.70 | BCL2L1 (0.51) | MCL1RXRARXRB | |
| SCHEMBL6840172 | 0.70 | DYRK1A (0.69) | CLK1DYRK1ADYRK1BLMNA | |
| SCHEMBL4161689 | 0.70 | DYRK1A (1.00) | CLK1DYRK1ADYRK1BLMNASMN1; SMN2 | |
| SCHEMBL31081091 | 0.69 | STING1 (0.56) | — | |
| SCHEMBL3498640 | 0.68 | MAPT (0.52) | CLK1DYRK1ADYRK1BF9F10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100130737-A1 | Regulating Agent of GPR34 Receptor Function | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-05-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100130737-A1 | Regulating Agent of GPR34 Receptor Function | GPR34, GPR4, GPR6 | CLK1 3974/4885DYRK1A 3028/4885DYRK1B 2663/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.